Rice Partnership LLC Has $8.38 Million Position in Johnson & Johnson (NYSE:JNJ)

Rice Partnership LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 2.5% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 47,284 shares of the company’s stock after buying an additional 1,171 shares during the quarter. Johnson & Johnson comprises about 2.4% of Rice Partnership LLC’s portfolio, making the stock its 11th largest holding. Rice Partnership LLC’s holdings in Johnson & Johnson were worth $8,380,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Patron Partners LLC increased its holdings in Johnson & Johnson by 12.7% in the 1st quarter. Patron Partners LLC now owns 6,625 shares of the company’s stock valued at $1,174,000 after buying an additional 747 shares during the period. Palisade Capital Management LLC NJ grew its holdings in shares of Johnson & Johnson by 0.3% during the 1st quarter. Palisade Capital Management LLC NJ now owns 93,141 shares of the company’s stock valued at $16,507,000 after purchasing an additional 250 shares during the last quarter. Lmcg Investments LLC bought a new stake in shares of Johnson & Johnson during the 1st quarter valued at approximately $12,462,000. Capital Wealth Planning LLC grew its holdings in shares of Johnson & Johnson by 14.0% during the 1st quarter. Capital Wealth Planning LLC now owns 916,575 shares of the company’s stock valued at $162,445,000 after purchasing an additional 112,890 shares during the last quarter. Finally, Tandem Investment Advisors Inc. grew its holdings in shares of Johnson & Johnson by 4.8% during the 1st quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock valued at $57,867,000 after purchasing an additional 15,003 shares during the last quarter. Institutional investors and hedge funds own 68.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on JNJ shares. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a report on Friday, July 8th. Citigroup cut their target price on shares of Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. UBS Group cut their target price on shares of Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Finally, Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $165.39 on Friday. The company has a fifty day moving average of $170.60 and a 200-day moving average of $174.13. The firm has a market capitalization of $434.84 billion, a P/E ratio of 24.07, a P/E/G ratio of 3.12 and a beta of 0.61. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. Johnson & Johnson’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.48 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd were paid a $1.13 dividend. The ex-dividend date was Monday, August 22nd. This represents a $4.52 annualized dividend and a dividend yield of 2.73%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.